Immunohistochemical analysis was performed in regional lymph node cryostatic sections from 74 and bone marrow needle biopsy specimens from 10 cases with breast cancer. It is demonstrated that additional immunohistochemical study of regional lymph nodes using monoclonocal antibodies to epithelial antigens Egp34 and MUCI increases by 10.8% metastasis detection as compared to histological study alone. The presence of cancer cells in sternal needle biopsy specimens may be evidence of active hematogenic metastasis and requires more careful monitoring of the patients.
The study of different epithelial antigen expression has been performed in 183 breast cancers. In 73 patients regional lymph nodes were studied as well. Panepithelial antigen Egp-34 (Mab HEA-125) was expressed in 100% of primary tumors and metastases. Antigen MUC-1 (Mab ICO-25) was identified in 93% of breast cancers. Monomorphic type of expression in tumor cells was typical for Egp-34, MUC-1 being in certain cases expressed as a proportion of cells. Additional immunohistochemical study of regional lymph nodes with Mab to Egp34 and MUC-1 provides a 10% increase in the rate of breast cancer metastases detection compared to histological examination alone. The carcinoembryonic antigen (CEA) was useful in identification of metastases only in CEA-positive breast cancers.
Иммунологические исследования рака молочной железы (РМЖ) ведутся по самым различным направлениям. Среди них - поиск маркеров, ассоциированных с прогнозом заболевания, иммунологическое стадирование опухоли, анализ взаимодействий опухоли и иммунной системы, создание противораковых вакцин и многое другое. Нами на протяжении последних 15 лет накоплен опыт иммунофенотипического изучения РМЖ. Представленные в работе результаты указывают на целесообразность исследования двух новых маркеров клеток РМЖ. ТФР-рецептор способствует росту гематогенных и лимфогенных метастазов РМЖ, и отсутствие CD71 является фактором благоприятного прогноза в сроки от 1 года до 6 лет после операции. Биологическая роль углеводного антигена LU-BCRUG7 на сегодняшний день не известна, отсутствие этой детерминанты на мембране опухолевых клеток является фактором более благоприятного прогноза при На стадии РМЖ.
Приведенный случай первичной множественности интересен необычным сочетанием доброкачественной и злокачественных опухолей различного гистогенеза у одной пациентки. Это вызвало определенные трудности в постановке диагноза и дальнейшей тактики лечения.Практическим врачам нужно помнить о необходимости тщательного гистологического исследования быстрорастущих фиброаденом молочных желез.
The presence of humoral antibodies specifically recognizing structural proteins of murine mammary tumor virus was studied in indirect immuno-enzymatic reaction, in 79 patients with suspected tumors of the breast. Diagnosis was verified after surgery by histological procedures. Said antibodies were detected in 13% of patients with benign tumors, lymphomas and mammary lymphosarcomas. However, in the breast cancer group including patients with T1-2N0M0 and T1N1M0, antibodies were identified in 85.7% of sera. It is suggested that patients with breast tumors who have antibodies to murine mammary tumor virus develop a specific nosological type of tumor which arises at reproductive age and is capable of high-rate growth and low-level metastatic spreading. Feasibility of application of said procedure for early detection of breast cancer is discussed.
Certain expression regularities of different markers in human breast cancer cells are demonstrated. Monomorphic determinants of HLA class II antigen are detected only in case of HLA class I expression and cancer-embryonal antigen (CEA); the latter is combined with HLA class I and ICO-84 antigens at a significantly higher rate. The expression effect of CEA and HLA-DR on the metastatic spreading rate of regional lymph nodes is marked. A heterogeneity of the single tumour and in patients with malignant breast cancer is determined by the presence of the "leucocytic" antigens and CEA. In parallel studies monoclonal antibodies (MAB) HMFG-1 and a common epithelial antigen are assayed. The antigen interacting with MAB HEA-125 is characterized by the monomorphic expression.